Please join us in one of the most exciting an welcoming places on earth…Singapore…for the 22nd World Congress of Sexual Health. more information will be available on this blog an don the WAS website as the details are being confirmed.
Looking forward to seeing you there for a robust scientific exchange as well as expereincing exciting social adventures.
Last year, The National Sex Ed Conference had many knowledgable and engaging speakers:
- Dr. Ruth Westheimer
- Jane Fonda
- Cindy Lee Alves
- Dr. David Satcher
- John Harvey Kellog
- Debby Herbenick
- Ileana Jiménez
- Carolyn Cooperman
One of the workshops inlcuded discussion on the best practices approaches to educating about bixsexuality and the biggest sex ed myths were addressed by Megara Bell and Brian Flaherty.
I am honored to be invited to give a keynote at this year’s National Sex Ed conference (Dec 3, 2015). This is by far the most creative conference video I have ever seen. Such an elegant way to emphasis on the importance of creativity in our work.
National Sex Ed Conference Video
Registration is open now.
After being rejected twice, the “female viagra” (flibanserin) has resurfaced and this time it looks like it may be here to stay.
Is the drug effective?
The effect of flibanserin is described “modest.” In company studies, women taking flibanserin reported a slight increase in sexually satisfying events each month. Their answers to separate questionnaires indicated they experienced a slight increase in desire and a slight decrease in stress.
While FDA scientists describe these effects as “small,” they were significant enough to meet FDA effectiveness standards.
The FDA panelists acknowledged this week that flibanserin will not help all patients. The percentage of patients reporting positive results with flibanserin was only 10 to 15 percent higher than among patients taking a placebo. That suggests as few as 1 in 10 patients may actually benefit from the drug, according to some FDA advisers.
Overall, the drug got positive voting 18-6 vote in favor of approval to become the first medication indicated for premenopausal women with Hypoactive Sexual Desire Disorder (HSDD).
Read more about on New Haven Register Health